TABLE 2.
Role of LINC00511 in gastric cancer.
| Cancer type | Expression/Role | Samples/Assessed cell lines | Pathways | Targets/Regulators | Function | Ref |
|---|---|---|---|---|---|---|
| Gastric Cancer (GC) | Upregulated/Oncogene | AGS, HGC‐27, ACP01, SNU‐1, Het‐1A | PI3K/AKT pathway | miR‐195‐5p/SOX4 | After epigenetically suppressing PTEN to activate the PI3K/AKT pathway by engaging EZH2, SOX4-induced LINC00511 stimulated SOX4 via ceRNA pattern, promoting GC cell proliferation, migration and stemness while preventing GC cell death | Wang et al. (2021) |
| Upregulated/Oncogene | MKN-45, BGC-823, HGC-27, MGC-803, GES-1 | LINC00511/miR-124-3p/PDK4 axis | miR-124-3p/PDK4 | By functioning as a ceRNA to control the miR-124-3p/PDK4 axis, which could be a viable therapeutic option for GC, LINC00511 encourages the tumor cell growth | Sun et al. (2020a) | |
| Upregulated/Oncogene | 25 patients with gastric cancer/GES-1, AGS, SGC7901, BGC823, MKN45, MGC803 | MAPK signaling pathway | miR-515-5p | By influencing miR-515-5p, LINC00511 can stimulate the expansion of tumor cells, suggesting that it might be a viable option for the creation of anti-cancer medications | Wang et al. (2020a) | |
| Upregulated/Oncogene | 35 TNTPs/GES1, GC27, BGC823, MGC803, SGC7901 | LINC00511/miR-625-5p/NFIX axis | miR-625-5p/NFIX | By targeting NFIX in GC cells, LINC00511 is a tumor activator to sponge miR-625-5p. Elimination of this lncRNA might be viewed as a treatment option for GC therapy | Chen et al. (2019a) | |
| Upregulated/Oncogene | 80 patients with GC/GES-1, MGC, HGC, MKN25, MKN28 | LINC00511/miR-124-3p/EZH2 pathway | miR-124-3p/EZH2 pathway | In sufferers with GC, LINC00511 is linked to a poor overall survival. It was predicted that LINC00511 would be a suitable target for treating human GC since it has a function in encouraging the cancerous cells growth | Huang et al. (2020) | |
| Upregulated/Oncogene | 50 TNTPs/MKN28, BGC-823, MKN-45, MGC-803, SGC-7901, GES-1 | STAT3 signal pathway | miR-625-5p/STAT3 | By controlling miR-625-5p and STAT3, LINC00511 encourages GC cell growth, implying that LINC00511 has oncogenic capabilities that influence the formation of GC. | Cui et al. (2021) | |
| Upregulated/Oncogene | AGS, SGC7901 | LINC00511/miR-29b/KDM2A axis | miR-29b/KDM2A axis | In GC, LINC00511 depletion boosted the apoptosis and hindered cell growth. It is possible to exploit the LINC00511/miR-29b/KDM2A axis as a viable treatment option for GC. | Zhao et al. (2020) |